Yoshitsu Co Ltd (TKLF) Stock

TOKYO , Dec. 18, 2024 /PRNewswire/ -- Tokyo Lifestyle Co., Ltd. ("Tokyo Lifestyle" or the "Company") (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, as well as other products in Hong Kong, Japan, North America and the United Kingdom, today announced its unaudited financial results for the first six months of fiscal year 2025 ended September 30, 2024.

TOKYO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Yoshitsu Co., Ltd (“Yoshitsu” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products and other products in Hong Kong, Japan, North America, and the United Kingdom, today announced plans to change its corporate name to “Tokyo Lifestyle Co., Ltd.” as part of its growth strategy in response to evolving market conditions and to strengthen its brand identity. The change will take effect on October 31, 2024.

TOKYO, Japan, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Yoshitsu Co., Ltd ("Yoshitsu" or the "Company") (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, as well as other products in Hong Kong, Japan, North America, and the United Kingdom, today announced that it has been named a Gold Stevie® Award winner in the "Company of the Year - Retail - Medium-size" category at the 21st Annual International Business Awards® (“IBAs”). See the official website of the IBAs at https://stevieawards.com/iba/company-organization-awards-winners-0 for details.

TOKYO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Yoshitsu Co., Ltd ("Yoshitsu" or the "Company") (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, as well as other products in Hong Kong, Japan, North America, and the United Kingdom, today announced that its Hong Kong subsidiary, Tokyo Lifestyle Limited (“TLS”), entered into a US$2.75 million loan agreement (the “Agreement”) on July 10, 2024 with a wholly-owned subsidiary of Tasly (International) Healthcare Investment & Development Company Limited (“Tasly”), a pharmaceutical conglomerate based in China, to support TLS's future growth and development.